FDA accepts Iroko lower dose submicron diclofenac NDA for review
According to the firm, the lower dose submicron diclofenac NDA submission included data from a study conducted on 428 healthy adults in a Phase 3 multi-center, randomized process,
Anixa Biosciences has secured a patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology.